Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of 89Zr-DFO-HuMab-5B1 (MVT-2163) With HuMab-5B1 (MVT-5873) in Patients With Pancreatic Cancer or Other CA19-9 Positive Malignancies

NCT02687230 is registered in ClinicalTrials.gov with BioNTech Research & Development, Inc. as lead sponsor.

NCT NCT02687230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02687230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of 89Zr-DFO-HuMab-5B1 (MVT-2163) With HuMab-5B1 (MVT-5873) in Patients With Pancreatic Cancer or Other CA19-9 Positive Malignancies
Lead sponsor
BioNTech Research & Development, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
July 11, 2016
Completion date
May 5, 2017
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic carcinoma, tumors that express ca19-9